ZEVRA THERAPEUTICS, INC. ZVRA
ZEVRA THERAPEUTICS, INC. statistics & valuation
Market cap$747.8M
P / E9.0×
P / S7.0×
P / B4.8×
Net margin78.2%
Return on equity53.8%
FCF margin-2.3%
Net cash$478,000
Enterprise value USD$747.3M
Earnings yield EBIT/EV-8.4%
Return on capital-25.6%
Graham number -20.8%$9.06
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports. The Graham number is Benjamin Graham's rough maximum fair value ($9.06); a green figure means the price is below it.
Profitability & efficiency
Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating margin | -59.1% | -368.5% | -180.6% | -418.9% | 27.0% | -42.2% | -158.4% | — | — | — |
| Net margin | 78.2% | -446.9% | -167.7% | -263.5% | -29.9% | -96.0% | -191.0% | — | — | — |
| FCF margin | -2.3% | -295.0% | -123.2% | -185.1% | 36.1% | -14.8% | -185.1% | — | — | — |
| Return on assets | 29.2% | -59.2% | -26.7% | -23.2% | -6.4% | -113.8% | -233.4% | -211.1% | -82.7% | -19.5% |
| Return on equity | 53.8% | -266.0% | -74.4% | -35.6% | -8.4% | 19.2% | 32.9% | 84.8% | 75.4% | 88.3% |
| Debt / equity | 0.40× | 1.50× | 0.08× | — | — | -1.02× | -1.04× | -1.22× | -1.61× | — |
| Current ratio | 5.68 | 2.53 | 1.18 | 7.72 | 27.20 | 1.11 | 1.28 | 1.98 | 3.99 | 11.19 |
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.